SABINA INTERNATIONAL
NCT03857178 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8617
Last updated 2021-02-11
Summary
The aim of the study is to describe the prescribing pattern of the different types of medications which are used to treat asthma, across multiple countries.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-29
- Primary Completion
- 2020-05-06
- Completion
- 2020-05-06
Countries
- Argentina
Study Locations
More Related Trials
-
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
NCT01232335 ·Status: COMPLETED
-
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
NCT00505388 ·Status: COMPLETED
-
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone
NCT01458886 ·Status: WITHDRAWN ·Phase: PHASE2
-
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
NCT01397162 ·Status: TERMINATED ·Phase: PHASE2
-
Symbicort Turbuhaler 30/60 Clinical Experience Investigation
NCT01232348 ·Status: COMPLETED
-
As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma
NCT00382889 ·Status: COMPLETED ·Phase: PHASE3
-
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
NCT00385593 ·Status: TERMINATED ·Phase: PHASE3
-
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
NCT00812357 ·Status: COMPLETED
-
Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
NCT01117116 ·Status: COMPLETED ·Phase: NA
-
A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma
NCT02182661 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy
NCT01711840 ·Status: COMPLETED
-
A Trial of HBM9378 in Healthy Chinese Subjects
NCT05790694 ·Status: COMPLETED ·Phase: PHASE1
-
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
NCT00419757 ·Status: COMPLETED ·Phase: PHASE3
-
Supporting Asthma Management Behaviors in Aging Adults
NCT02316223 ·Status: COMPLETED ·Phase: NA
-
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
NCT01823016 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
NCT00573222 ·Status: COMPLETED
-
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
NCT00235911 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Determine The Effect Of SB-480848 On Asthma
NCT00368576 ·Status: COMPLETED ·Phase: PHASE1
-
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
NCT00785733 ·Status: COMPLETED
-
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
NCT00319306 ·Status: COMPLETED ·Phase: PHASE3
-
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
NCT00479739 ·Status: COMPLETED ·Phase: PHASE4
-
Study In Asthma Control
NCT00273026 ·Status: TERMINATED ·Phase: PHASE4
-
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
NCT00358488 ·Status: COMPLETED ·Phase: PHASE2
-
Device Mixing in Asthma, a General Practice Research Database Study
NCT01313585 ·Status: COMPLETED
-
Study in Adult Patients With Moderate to Severe Asthma
NCT04886999 ·Status: COMPLETED ·Phase: PHASE3